The receptor protein tyrosine kinase 7 (PTK7) was recently shown to participate in noncanonical Wnt/planar cell polarity signalling during mouse and frog embryonic development. In this study, we report that PTK7 interacts with b-catenin in a yeast two-hybrid assay and mammalian cells. PTK7-deficient cells exhibit weakened b-catenin/T-cell factor transcriptional activity on Wnt3a stimulation. Furthermore, Xenopus PTK7 is required for the formation of Spemann's organizer and for Siamois promoter activation, events that require b-catenin transcriptional activity. Using epistatic assays, we demonstrate that PTK7 functions upstream from glycogen synthase kinase 3. Taken together, our data reveal a new and conserved role for PTK7 in the Wnt canonical signalling pathway.
The pseudo tyrosine kinase receptor 7 (PTK7) is an orphan tyrosine kinase receptor assigned to the planar cell polarity pathway. It plays a major role during embryogenesis and epithelial tissue organization. Here we found that PTK7 is also expressed in normal myeloid progenitors and CD34 ؉ CD38 ؊ bone marrow cells in humans. We performed an immunophenotyping screen on more than 300 patients treated for hematologic malignancies. We demonstrated that PTK7 is expressed in acute myeloid leukemia (AML) and is mostly assigned to granulocytic lineage differentiation. Patients with PTK7-positive AML are more resistant to anthracycline-based frontline therapy with a significantly reduced leukemia-free survival in a multivariate analysis model. In vitro, expression of PTK7 in cultured leukemia cells promotes cell migration, cell survival, and resistance to anthracycline-induced apoptosis. The intracellular region of PTK7 is required for these effects. Furthermore, we efficiently sensitized primary AML blasts to anthracycline-mediated cell death using a recombinant soluble PTK7-Fc protein. We conclude that PTK7 is a planar cell polarity component expressed in the myeloid progenitor compartment that conveys promigratory and antiapoptotic signals into the cell and that represents an independent prognosis factor of survival in patients treated with induction chemotherapy. (Blood. 2010;116(13):2315-2323)
1571 Poster Board I-596 The pseudo tyrosine kinase receptor 7 (PTK7) is an orphean tyrosine kinase receptor assigned to the planar cell polarity pathway (PCP). It has been recently described and plays a major role during embryogenesis and epithelial tissue organisation. To date there is no report in the litterature considering a potential implication in hematopoiesis. In silico and in vitro analysis found that PTK7 was also expressed in normal myeloid progenitors and CD34+ CD38- bone marrow cells in humans. Preliminary results from our team showed that PTK7 was also expressed in various leukemic cell lines such Jurkat, TF-1 or KG-1a. We decided to perform a wide range multicolour immunophenotyping screen on patients with acute myeloid leukemia (AML) at diagnosis and to investigate the role of PTK7 in AML in vitro. More than 250 patient samples were evaluated and we demonstrated that PTK7 was largely expressed in AML as 72% of the samples were PTK7 positive. Its expression mostly correlates with granulocytic lineage differentiation. PTK7 expression was associated with a lower WBC count at diagnosis and a lower frequency of extramedullary disease whatever was FAB subtype. Interestingly, PTK7 expression was associated with some cytogenetic subgroups including CBF-AML and APL. There was no correlation with molecular subgroups (i.e. FLT3-ITD/NPM1/CEBPA status). Overall Survival and Relapse Free Survival were evaluated in non-APL patients treated with induction chemo (n=182). Patients with PTK7 positive AML are more resistant to anthracycline-based frontline therapy with a significantly reduced Relapse Free Survival in a multivariate analysis model integrating all pre treatment variables (2 year probability of RFS= 29% vs 66% for PTK7 negative patients, p= 0.003). Forrest plot analysis showed that the negative impact of PTK7 expression was the most significant in intermediate cytogenetic risk subgroup and when PTK7 was aberrantly expressed in M4-M5 FAB subtypes. There was no demonstrated impact on CR. In cultured cells, expression of PTK7 promotes leukemia cell migration, cell survival and resistance to anthracyclin-induced apoptosis. There was no effect of PTK7 expression on cell proliferation in tritiated thymidine assay. In the absence of known inhibitor of PTK7, we produced a soluble recombinant PTK7-Fc protein that efficiently competes for PTK7 functions in cell migration and survival assays in cell lines and primary AML samples. These data were confirmed using a shRNA strategy. We conclude that PTK7 is a PCP component expressed in the myeloid progenitor compartment that conveys promigratory and anti-apoptotic signal to leukemia cells. Its use as a potential biomarker or therapeutical target should be investigated. Disclosures No relevant conflicts of interest to declare.
The planar cell polarity pathway plays a major role in embryogenesis and tissue organisation. Recent genetic studies have highlighted the role of novel receptors and signaling molecules implicated in this pathway. Amongst the receptors, the pseudo tyrosine kinase receptor 7 (PTK7) is an orphean tyrosine kinase receptor with kinase-dead activity. Knock-out of PTK7 in mice strongly affects embryonic development leading to a major neural tube defect. Presence of PTK7 was previously investigated in epithelial and endothelial cells that both express the receptor. In normal donors, we found no expression of PTK7 in peripheral blood (n=5) whereas PTK7 expression was found with low levels in PBPC after G-CSF stimulation (n=3) and high levels in normal myeloid progenitors and CD34+ CD38− bone marrow cells (n=3). Overexpression of PTK7 was already described in solid tumors including breast, lung and pancreatic cancers. We decided to study the potential implication of PTK7 in haematological malignancies. We performed a wide range multicolour immunophenotyping screen on more than 240 patient samples treated at Institut Paoli-Calmettes and 10 leukemia cell lines. In hematologic malignancies, we demonstrated that PTK7 was widely expressed in AML (136 of 195 patients) and in the most immature subsets of Acute lymphoblastic (5 of 20 patients) or biphenotypic leukaemia (3 of 3 patients). We found no expression of PTK7 in chronic disorder such low grade NHL (n=7), CLL (n=6) or Chronic Myelomonocytic Leukemia (n=3). In AML, we demonstrated that PTK7 expression mostly correlates with granulocytic lineage differentiation and that it could be partially expressed in AML 4 or 5 subsets. Flow cytometry analysis confirmed the co-expression of PTK7 with granulocytic lineage markers and that PTK7 expression in myelomonocytic leukaemia was limited to the myeloid subset of blasts. The strongest immunophenotyping correlation was found with CD117/c-Kit expression (p<0.001) and PTK7 Mean Fluorescence Intensity directly correlates with c-Kit MFI (p=0.001). Interestingly, stimulation of cultured TF1 cells (that endogenously express c-Kit and PTK7) with SCF triggered an increased expression of PTK7. Correlation between PTK7 expression and biological or clinical features was also evaluated. We demonstrated that PTK7 expression clustered with some cytogenetic subsets (high levels in CBF AML (n=19) or APL (n=13), low levels in FLT3 mutated AML(n=17) or complex karyotype (n=20)). We also found that PTK7 expression was associated with a lower WBC count at diagnosis (p=0.001) and a lower frequency of extramedullary disease (p<0.001) in whole population and in both AML1–3 and AML 4–5 subgroups. We report here novel findings that potentially implicate ptk7, a PCP gene, in hematopoiesis and AML. In vitro, we showed that ectopic expression of PTK7 promotes cell migration, cell survival and resistance to anthracyclin-induced apoptosis. Ongoing works are currently investigating which molecular mechanisms regulate PTK7 functions in normal and pathological situations.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.